BRPI0718862B8 - composto, composição farmacêutica que o contém e uso do composto - Google Patents

composto, composição farmacêutica que o contém e uso do composto

Info

Publication number
BRPI0718862B8
BRPI0718862B8 BRPI0718862A BRPI0718862A BRPI0718862B8 BR PI0718862 B8 BRPI0718862 B8 BR PI0718862B8 BR PI0718862 A BRPI0718862 A BR PI0718862A BR PI0718862 A BRPI0718862 A BR PI0718862A BR PI0718862 B8 BRPI0718862 B8 BR PI0718862B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
composition containing
opo3h2
amino acid
Prior art date
Application number
BRPI0718862A
Other languages
English (en)
Inventor
Hubschwerlen Christian
Specklin Jean-Luc
Panchaud Philippe
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39170372&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0718862(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0718862A2 publication Critical patent/BRPI0718862A2/pt
Publication of BRPI0718862B1 publication Critical patent/BRPI0718862B1/pt
Publication of BRPI0718862B8 publication Critical patent/BRPI0718862B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composto, composição farmacêutica que o contém e uso do composto. a invenção refere-se a novos antibióticos quiméricos da fórmula i em que r1 representa oh, opo3h2 ou ocor5; r2 representa h, oh or opo3h2; a representa n ou cr6; r3 representa h ou flúor; r4 é h, (c1-c3) alquila, ou cicloalquila; r5 é o resíduo de um aminoácido que se apresenta naturalmente, do enantiômero de um aminoácido que se apresenta naturalmente, ou de dimetilaminoglicina; r6 representa h, alcoxila ou halogênio; e n é 0 ou 1; e aos sais (em particular os sais farmaceuticamente aceitáveis) dos compostos da fórmula i. estes compostos quiméricos são de utilidade na manufatura de medicamentos para o tratamento de infecções (por exemplo, infecções bacterianas).
BRPI0718862A 2006-11-10 2007-11-09 composto, composição farmacêutica que o contém e uso do composto BRPI0718862B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB06/054189 2006-11-10
IB2006054189 2006-11-10
PCT/IB2007/054557 WO2008056335A1 (en) 2006-11-10 2007-11-09 5-hydroxymethyl-oxazolidin-2-one derivatives

Publications (3)

Publication Number Publication Date
BRPI0718862A2 BRPI0718862A2 (pt) 2013-12-17
BRPI0718862B1 BRPI0718862B1 (pt) 2020-10-13
BRPI0718862B8 true BRPI0718862B8 (pt) 2021-05-25

Family

ID=39170372

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718862A BRPI0718862B8 (pt) 2006-11-10 2007-11-09 composto, composição farmacêutica que o contém e uso do composto

Country Status (28)

Country Link
EP (1) EP2086968B1 (pt)
JP (2) JP4484965B2 (pt)
KR (1) KR101118402B1 (pt)
CN (1) CN101535305B (pt)
AR (1) AR063788A1 (pt)
AT (1) ATE544764T1 (pt)
AU (1) AU2007318901B2 (pt)
BR (1) BRPI0718862B8 (pt)
CA (1) CA2668280C (pt)
CL (1) CL2007003232A1 (pt)
CY (1) CY1112696T1 (pt)
DK (1) DK2086968T3 (pt)
ES (1) ES2380388T3 (pt)
HK (1) HK1136276A1 (pt)
HR (1) HRP20120385T1 (pt)
IL (1) IL198645A (pt)
MA (1) MA30960B1 (pt)
MX (1) MX2009004764A (pt)
MY (1) MY148847A (pt)
NO (1) NO344727B1 (pt)
NZ (1) NZ577538A (pt)
PL (1) PL2086968T3 (pt)
PT (1) PT2086968E (pt)
RU (1) RU2453546C2 (pt)
SI (1) SI2086968T1 (pt)
TW (1) TWI374138B (pt)
WO (1) WO2008056335A1 (pt)
ZA (1) ZA200904028B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031443A1 (en) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
ES2308171T3 (es) 2003-04-30 2008-12-01 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Uso de antibioticos hibridos de oxazolidinona-quinolina para el tratamiento del antrax y de otras infecciones.
DE10340485B4 (de) 2003-09-03 2015-05-13 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Verfahren zur Herstellung von Oxazolidinon-Chinolon Hybriden
US8158797B2 (en) 2003-12-18 2012-04-17 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Oxazolidinone-quinolone hybrid antibiotics
RU2371443C2 (ru) † 2003-12-18 2009-10-27 Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми Оксазолидинон-хинолонгибридные антибиотики
US8124623B2 (en) 2006-11-10 2012-02-28 Actelion Pharmaceuticals Ltd. 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials
DK2296651T3 (da) * 2008-05-09 2012-09-24 Actelion Pharmaceuticals Ltd 5-hydroxymethyl-oxazolidin-2-on-derivater til behandling af bakterielle intestinale sygdomme
IN2014CN04126A (pt) * 2011-11-08 2015-07-10 Actelion Pharmaceuticals Ltd
AU2014273510B2 (en) 2013-05-28 2019-10-10 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Oxazolidinone-quinolone hybrid antibacterials for the parenteral treatment or prophylaxis of bacterial diseases
AU2014273471B2 (en) 2013-05-28 2019-10-03 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
WO2016079757A2 (en) * 2014-11-19 2016-05-26 Symed Labs Limited Novel processes for preparing 5-hydroxymethyl-oxazolidin-2-one derivatives
US10851079B2 (en) 2016-02-26 2020-12-01 Otsuka Pharmaceutical Co., Ltd. Piperidine derivative
US10087171B2 (en) 2016-12-19 2018-10-02 Actelion Pharmaceuticals Ltd Crystalline forms of cadazolid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1156597A3 (ru) * 1982-04-28 1985-05-15 Е.И.Дюпон Де Немур Энд Компани (Фирма) Способ получени производных 3-( @ -алкилсульфонилфенил)оксазолидинона или их фармацевтически приемлемых кислотно-аддитивных солей
US4461773A (en) * 1982-09-15 1984-07-24 E. I. Dupont De Nemours And Company P-Oxooxazolidinylbenzene compounds as antibacterial agents
US6608081B2 (en) * 1999-08-12 2003-08-19 Ortho-Mcneil Pharmaceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
US6413981B1 (en) * 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
CA2424402A1 (en) * 2000-12-21 2002-08-01 Pharmacia & Upjohn Company Antimicrobial quinolone derivatives and use of the same to treat bacterial infections
AU2002256995A1 (en) * 2001-02-07 2002-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods
ES2308171T3 (es) * 2003-04-30 2008-12-01 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Uso de antibioticos hibridos de oxazolidinona-quinolina para el tratamiento del antrax y de otras infecciones.
CN100544719C (zh) * 2003-04-30 2009-09-30 莫弗凯姆联合化学股份公司 噁唑烷酮-喹啉杂化物抗生素用于制备治疗炭疽和其它感染的药物中的用途
KR100854211B1 (ko) * 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
RU2371443C2 (ru) * 2003-12-18 2009-10-27 Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми Оксазолидинон-хинолонгибридные антибиотики

Also Published As

Publication number Publication date
MA30960B1 (fr) 2009-12-01
CA2668280C (en) 2015-02-10
CN101535305B (zh) 2013-09-18
MY148847A (en) 2013-06-14
TWI374138B (en) 2012-10-11
TW200829580A (en) 2008-07-16
RU2009121812A (ru) 2010-12-20
KR20090075875A (ko) 2009-07-09
ATE544764T1 (de) 2012-02-15
KR101118402B1 (ko) 2012-03-07
CY1112696T1 (el) 2016-02-10
MX2009004764A (es) 2009-05-21
WO2008056335A1 (en) 2008-05-15
SI2086968T1 (sl) 2012-06-29
PT2086968E (pt) 2012-04-13
IL198645A0 (en) 2010-02-17
BRPI0718862B1 (pt) 2020-10-13
NO344727B1 (no) 2020-03-23
ES2380388T3 (es) 2012-05-11
JP2010132677A (ja) 2010-06-17
CL2007003232A1 (es) 2008-06-27
ZA200904028B (en) 2010-08-25
CN101535305A (zh) 2009-09-16
AU2007318901B2 (en) 2013-03-14
NZ577538A (en) 2011-11-25
AR063788A1 (es) 2009-02-18
HRP20120385T1 (hr) 2012-06-30
BRPI0718862A2 (pt) 2013-12-17
HK1136276A1 (en) 2010-06-25
RU2453546C2 (ru) 2012-06-20
AU2007318901A1 (en) 2008-05-15
NO20092209L (no) 2009-06-09
JP2010509314A (ja) 2010-03-25
DK2086968T3 (da) 2012-03-19
EP2086968B1 (en) 2012-02-08
JP5490553B2 (ja) 2014-05-14
PL2086968T3 (pl) 2012-07-31
JP4484965B2 (ja) 2010-06-16
CA2668280A1 (en) 2008-05-15
IL198645A (en) 2014-05-28
EP2086968A1 (en) 2009-08-12

Similar Documents

Publication Publication Date Title
BRPI0718862B8 (pt) composto, composição farmacêutica que o contém e uso do composto
BRPI0809977A8 (pt) Uso de um composto, compostos e composição farmacêutica que o contém
AR063925A1 (es) Antibacteriales 5-hidroximetil -oxazolidin-2-ona composicion farmaceutica que los comprende y su uso para tratar o prevenir infecciones bacterianas
BR0314113A (pt) Derivados de amino propanol
BRPI0921701B8 (pt) Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende
GEP20115359B (en) Fused cyclic compounds
BR0214031A (pt) Compostos de heteroarila azabicìclico substituìdos para o tratamento de doenças
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
BRPI0408815A (pt) moduladores alostéricos positivos do receptor nicotìnico da acetilcolina
BRPI0922220B8 (pt) uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
BRPI1009637A2 (pt) composto, composição e uso de um composto
BRPI0610907A2 (pt) composto ou precursores hidrolisÁveis in vivo ou sal farmaceuticamente aceitÁvel do mesmo, mÉtodos de tratamento ou profilaxia de uma doenÇa ou condiÇço na qual a modulaÇço do receptor de mch1 É benÉfica e de tratamento ou profilaxia de doenÇas, composiÇço farmacÊutica, e, uso de um composto
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
ME01456B (me) Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola
BR0311984A (pt) Difenilazetidinonas substituìdas cationicamente, processo para a sua preparação, medicamentos contendo estes compostos e sua aplicação
BRPI0706992C1 (pt) composto de fórmula (i) e formulação farmacêutica
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112015031878A2 (pt) composição farmacêutica
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
CL2007003042A1 (es) Compuestos derivados del acido tetrahidro-naftalen-1-carboxilico sustituidos con piperidina o piperazina; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica; procedimiento de preparacion; y uso para el tratamiento de arte
BRPI0409739A (pt) composto, composição farmacêutica, uso de composto, e, método para o tratamento de uma doença ou de um distúrbio
BRPI0810399B8 (pt) composto, composição farmacêutica que o contém e uso do mesmo
BR0210667A (pt) Derivados de oxazolidinonas como agentes antibacterianos
BRPI0708278B8 (pt) forma cristalina "a" do sal de arginina de perindopril, seu uso, processo para sua preparação e composição farmacêutica
BRPI0720684A8 (pt) Composto, medicamento, composição farmacêutica que contém e uso do composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/11/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF